Regarding the impact of lenalidomide on the BME, treatment with lenalidomide decreases levels of CXCL12 production from normal as well as MDS-MSCs (Figure 1) (Ferrer et al., 2013). Here, CXCL12 is linked to myelodysplastic syndrome.